NASDAQ:CADL Candel Therapeutics (CADL) Stock Price, News & Analysis $5.28 +0.39 (+7.98%) Closing price 04:00 PM EasternExtended Trading$5.24 -0.04 (-0.76%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Candel Therapeutics Stock (NASDAQ:CADL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Candel Therapeutics alerts:Sign Up Key Stats Today's Range$4.91▼$5.3450-Day Range$4.39▼$8.9852-Week Range$3.79▼$14.60Volume1.16 million shsAverage Volume1.47 million shsMarket Capitalization$249.40 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company OverviewCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Read More… Candel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCADL MarketRank™: Candel Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 633rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCandel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCandel Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Candel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Candel Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Candel Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCandel Therapeutics has a P/B Ratio of 12.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Candel Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.57% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Candel Therapeutics has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCandel Therapeutics does not currently pay a dividend.Dividend GrowthCandel Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.57% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Candel Therapeutics has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment1.80 News SentimentCandel Therapeutics has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Candel Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for CADL on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $320,022.00 in company stock.Percentage Held by Insiders41.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.93% of the stock of Candel Therapeutics is held by institutions.Read more about Candel Therapeutics' insider trading history. Receive CADL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CADL Stock News HeadlinesCandel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025April 23, 2025 | globenewswire.comCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade ...April 3, 2025 | seekingalpha.comElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...May 2, 2025 | American Hartford Gold (Ad)Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409April 2, 2025 | markets.businessinsider.comCandel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409April 1, 2025 | proactiveinvestors.comCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma PatientsApril 1, 2025 | globenewswire.comCandel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMIMarch 29, 2025 | proactiveinvestors.comCandel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMIMarch 29, 2025 | proactiveinvestors.comSee More Headlines CADL Stock Analysis - Frequently Asked Questions How have CADL shares performed this year? Candel Therapeutics' stock was trading at $8.68 at the beginning of 2025. Since then, CADL stock has decreased by 39.2% and is now trading at $5.28. View the best growth stocks for 2025 here. How were Candel Therapeutics' earnings last quarter? Candel Therapeutics, Inc. (NASDAQ:CADL) released its earnings results on Thursday, March, 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.17. When did Candel Therapeutics IPO? Candel Therapeutics (CADL) raised $72 million in an initial public offering (IPO) on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are Candel Therapeutics' major shareholders? Top institutional shareholders of Candel Therapeutics include Bank of New York Mellon Corp (0.13%), Rhumbline Advisers (0.07%), Stratos Wealth Advisors LLC (0.05%) and Janney Montgomery Scott LLC (0.04%). Insiders that own company stock include Estuardo Aguilar-Cordova, Paul Peter Tak, Francesca Barone, William Garrett Nichols, Seshu Tyagarajan, Charles Schoch, Jason Amello and Joseph C Papa. View institutional ownership trends. How do I buy shares of Candel Therapeutics? Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Candel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V). Company Calendar Last Earnings3/13/2025Today5/02/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CADL CIK1841387 Webwww.candeltx.com Phone617-916-5445FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$25.00 Low Stock Price Target$15.00 Potential Upside/Downside+297.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-629.29% Return on Assets-173.39% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$120,000.00 Price / Sales2,078.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book12.00Miscellaneous Outstanding Shares47,235,000Free Float18,966,000Market Cap$249.40 million OptionableOptionable Beta-0.95 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:CADL) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.